Recent Updates
Recently added Catalysts

PF-06852231

Phase 1

Healthy Volunteers | Small molecule | Other |Pfizer, Inc.|Last Updated: Feb 14, 2018

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment17
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03217604A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Doses of PF-06852231 in Healthy SubjectsPHASE1 COMPLETED 17Jul 13, 2017Feb 1, 2018Feb 14, 20181 Belgium
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)
Baseline up to 14 days after last dose of study medication

Treatment-related AE are any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent are events between first dose of study drug and up to Y days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to study drug is assessed either yes or no by the investigator. Participants with multiple occurrences of an AE within a category are counted once within the category.

Number of Participants With Laboratory Abnormalities
Baseline up to 14 days after last dose of study medication

Following parameters were analyzed for laboratory examination: hematology (hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); blood chemistry (blood urea nitrogen, creatinine, glucose, calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid albumin, total protein); urinalysis (decimal logarithm of reciprocal of hydrogen ion activity \[pH\], glucose, protein, blood, ketones, microscopy\[if urine tested positive for blood or protein\]).

Number of Participants With Clinically Significant Change From Baseline in Vital Signs
0, 1, 2, 4, 8, 12, 24, 48, 72 hours(h) post-dose

Following parameters were analyzed for examination of vital signs: systolic and diastolic blood pressure, pulse rate, and body temperature.

Number of Participants With Change From Baseline in Electrocardiogram (ECG) Findings
0, 1, 2, 4, 8, 12, 24, 48, 72 h post-dose

Absolute values and changes from baseline for ECG parameters

Abnormal rhythms as observed continuous cardiac telemetry
8 h post-dose

Cardiac rhythms measured by continuous cardiac monitoring

Secondary Endpoints
Maximum Observed Plasma Concentration (Cmax) for PF-06852231
0, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 h post-dose
Time to Reach Maximum Observed Plasma Concentration (Tmax) for PF-06852231
0, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 h post-dose
Area Under the Curve From Time Zero to Time of Last Measurable Plasma Concentration (AUClast) for PF-06852231
0, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 h post-dose
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelCROSSOVER
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
PlaceboPLACEBO_COMPARATORPlacebo
PF-06852231EXPERIMENTALSingle ascending doses of PF-06852231
Interventions
NameTypeDescription
PlaceboDRUGTreatment with placebo
PF-06852231DRUGTreatment with PF-06852231
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 55 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: 1. Healthy female subjects of non-childbearing potential and male subjects, who at the time of screening are between ages of 18 and 55 years inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination,...

Countries:Belgium
Unlock Eligibility Criteria